$PRQR News

Last published 2w ago

2w agoPRQRProQR to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesGlobeNewswireProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary sessionAX-0810 Phase 1 data to be featured in two poster presentations at
2mo agoPRQRProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies
2mo agoPRQRProQR to Participate in Upcoming Investor Conferences in September 2026GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies
3mo agoPRQRProQR Announces Second Quarter 2026 Operating and Financial ResultsGlobeNewswireFirst clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or scientific conference
4mo agoPRQRProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private PlacementGlobeNewswireLEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through
4mo agoPRQRProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing PlatformGlobeNewswireData from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up to 8-fold change
6mo agoPRQRProQR Announces First Quarter 2026 Operating and Financial ResultsGlobeNewswireAX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the
6mo agoPRQRProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies
6mo agoPRQRProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies
6mo agoPRQRProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies
7mo agoPRQRProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst EventGlobeNewswireAX-0810 clinical target engagement data in healthy volunteers on track for this quarter; biliary atresia selected as initial Phase 2 indicationAdditional programs advancing toward the clinic, including AX-0811 and
7mo agoPRQRProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory BoardGlobeNewswireProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR's AI-enabled drug discovery for Axiomer™ProQR establishes AI Advisory Board with leaders from industry
7mo agoPRQRProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
8mo agoLYEL PRQRLyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerGlobeNewswireClosing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH
8mo agoPRQRProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences ConferenceGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
9mo agoPRQRProQR Announces Planned Changes to Board CompositionGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies
10mo agoPRQRProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 OutlookGlobeNewswireInitial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected
11mo agoPRQRProQR to Participate in 8th Annual Evercore Healthcare ConferenceGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Announces Third Quarter 2025 Operating and Financial ResultsGlobeNewswireReceived CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseasesInitiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data from
1y agoPRQRProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR to Participate in Upcoming Investor Conferences in October 2025GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Announces Second Quarter 2025 Operating and Financial ResultsGlobeNewswireSubmitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor
1y agoPRQRProQR Announces Upcoming Presentation at RNA Editing SummitGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPGlobeNewswireFirst-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application
1y agoPRQRProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Announces First Quarter 2025 Operating and Financial ResultsGlobeNewswireAxiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership
1y agoPRQRProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences ConferenceGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of GrowthGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Announces Year End 2024 Operating and Financial ResultsGlobeNewswireAxiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four
1y agoPRQRProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing CollaborationGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Appoints Peter A. Beal, PhD, as Chief ADAR ScientistGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
1y agoPRQRProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced
2y agoPRQRProQR Announces Third Quarter 2024 Operating and Financial ResultsGlobeNewswireAX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and
2y agoPRQRProQR Announces Closing of Underwritten Public Offering and Concurrent Private PlacementGlobeNewswireLEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a company dedicated to changing lives through transformative RNA therapies based on its
2y agoPRQRProQR Prices $75 Million Underwritten Public Offering and Concurrent Private PlacementGlobeNewswireLEIDEN, Netherlands and CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a company dedicated to changing lives through transformative RNA therapies based on its
2y agoPRQRProQR Announces Proposed Underwritten Public Offering of Ordinary SharesGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a company dedicated to changing lives through transformative RNA therapies based on its
2y agoPRQRProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics SocietyGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it
2y agoPRQRProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare ConferenceGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
2y agoPRQRProQR Announces Second Quarter 2024 Operating and Financial ResultsGlobeNewswireAX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and trial design details
2y agoPRQRProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing SummitGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it
2y agoPRQRProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)Earnings Call Transcripts
2y agoPRQRProQR Announces First Quarter 2024 Operating and Financial ResultsGlobeNewswirePreclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier,
2y agoPRQRProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesGlobeNewswireProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing
2y agoPRQRProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024GlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
2y agoPRQRProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it
2y agoPRQRProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced
2y agoPRQRProQR Announces Year End 2023 Operating and Financial ResultsGlobeNewswirePreclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the
2y agoPRQRProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA EditingGlobeNewswireLEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced
2y agoPRQRProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024GlobeNewswirePlatform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3